Biotech | March 20, 2024
Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
The new campus has been designed as an employee-centred experience and ecosystem zone
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Almost 300 million people globally have chronic hepatitis B
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Subscribe To Our Newsletter & Stay Updated
